A Novel Pathological Prognostic Score (PPS) to Identify "Very High-Risk" Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST)

被引:10
|
作者
Liu, Xuechao [1 ,2 ,3 ]
Qiu, Haibo [1 ,2 ,3 ]
Wu, Zhiming [1 ,2 ,4 ]
Zhang, Peng [5 ]
Feng, Xingyu [6 ]
Chen, Tao [7 ]
Li, Yong [6 ]
Tao, Kaixiong [5 ]
Li, Guoxin [7 ]
Sun, Xiaowei [1 ,2 ,3 ]
Zhou, Zhiwei [1 ,2 ,3 ]
机构
[1] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Canc Ctr, Dept Gastr Surg, 651 East Dongfeng Rd, Guangzhou 510060, Guangdong, Peoples R China
[4] Sun Yat Sen Univ, Canc Ctr, Dept Urol, Guangzhou, Guangdong, Peoples R China
[5] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gen Surg, Wuhan, Hubei, Peoples R China
[6] Guangdong Gen Hosp, Dept Gen Surg, Guangzhou, Guangdong, Peoples R China
[7] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangzhou, Guangdong, Peoples R China
基金
美国国家科学基金会;
关键词
Gastrointestinal stromal tumor; Pathological prognostic score; Ki-67 labeling index; Mitotic index; Prognosis; ADJUVANT IMATINIB MESYLATE; KI-67; THERAPY; KIT; MANAGEMENT; MUTATIONS; DIAGNOSIS; SURVIVAL; IMPACT; TRIAL;
D O I
10.1007/s11605-018-3799-5
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background To determine the better risk stratification based on surgical pathology and to assess the clinical outcomes after curative resection with a new scoring system in high risk gastrointestinal stromal tumor (GIST) patients. Methods We retrospectively evaluated 506 high-risk GIST patients who underwent curative resection as initial treatment at four centers from 2001 to 2015. Results Multivariate analysis revealed that only Ki-67 labeling index (LI) and mitotic index were independent prognostic factors of overall survival (OS). For the two tumor-related pathological factors, Ki-67 LI > 7% and mitotic index >= 7/50 high power fields were allocated 1 point each. The total score was defined as the Pathological Prognostic Score (PPS). When Ki-67 LI and mitotic index were replaced by PPS, a multivariate analysis still identified PPS as an independent predictor of OS (HR 2.719; 95% CI 1.309-5.650; P = 0.007). Patients with a PPS of 0, 1, or 2 had a 5-year survival of 91.8, 79.8, and 51.0%, respectively (P = 0.001). Furthermore, an elevated PPS (PPS = 2) was associated with larger tumor size, non-stomach tumor, and open resection (all P < 0.05). Conclusion The PPS independently predicted postoperative survival in high-risk GIST, and it might facilitate the selection of appropriate treatment strategy for these patients.
引用
收藏
页码:2150 / 2157
页数:8
相关论文
共 50 条
  • [1] A Novel Pathological Prognostic Score (PPS) to Identify “Very High-Risk” Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST)
    Xuechao Liu
    Haibo Qiu
    Zhiming Wu
    Peng Zhang
    Xingyu Feng
    Tao Chen
    Yong Li
    Kaixiong Tao
    Guoxin Li
    Xiaowei Sun
    Zhiwei Zhou
    Journal of Gastrointestinal Surgery, 2018, 22 : 2150 - 2157
  • [2] Inflammatory biomarker correlations and prognosis in high-risk gastrointestinal stromal tumor patients: a multicenter retrospective analysis
    Wang, Tao
    Qi, Lihua
    Zhao, Yang
    Ma, Xiaolan
    Li, Tao
    BMC GASTROENTEROLOGY, 2025, 25 (01)
  • [3] Ki-67 labeling index may be a promising indicator to identify "very high-risk" gastrointestinal stromal tumor: a multicenter retrospective study of 1022 patients
    Liu, Xuechao
    Qiu, Haibo
    Zhang, Peng
    Feng, Xingyu
    Chen, Tao
    Li, Yong
    Tao, Kaixiong
    Li, Guoxin
    Sun, Xiaowei
    Zhou, Zhiwei
    HUMAN PATHOLOGY, 2018, 74 : 17 - 24
  • [4] Genetic heterogeneity of high risk gastrointestinal stromal tumor (GIST)
    Nishida, Toshirou
    Naito, Yoichi
    Honma, Yoshitaka
    Hirota, Seiichi
    Ichikawa, Hitoshi
    CANCER SCIENCE, 2018, 109 : 762 - 762
  • [5] Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study
    Rui Zhao
    Yong Wang
    Yuqian Huang
    Yaping Cui
    Lin Xia
    Yi Chen
    Wen Zhuang
    Yong Zhou
    Xiaoting Wu
    Scientific Reports, 7
  • [6] Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study
    Zhao, Rui
    Wang, Yong
    Huang, Yuqian
    Cui, Yaping
    Xia, Lin
    Chen, Yi
    Zhuang, Wen
    Zhou, Yong
    Wu, Xiaoting
    SCIENTIFIC REPORTS, 2017, 7
  • [7] Naples prognostic score, a novel prognostic score for patients with high- and intermediate-risk gastrointestinal stromal tumours after surgical resection
    Hao Wu
    Mengdi Fu
    Xiaozhou Xie
    Jianqiao Yang
    Yang Liu
    Fengying Du
    Zhen Fang
    Liang Shang
    Leping Li
    World Journal of Surgical Oncology, 20
  • [8] Naples prognostic score, a novel prognostic score for patients with high- and intermediate-risk gastrointestinal stromal tumours after surgical resection
    Wu, Hao
    Fu, Mengdi
    Xie, Xiaozhou
    Yang, Jianqiao
    Liu, Yang
    Du, Fengying
    Fang, Zhen
    Shang, Liang
    Li, Leping
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)
  • [9] A retrospective analysis of high-risk patients for mediastinoscopy
    Bulgen, Sibel Buluc
    Salihoglu, Ziya
    Demirkaya, Ahmet
    Yuceyar, Lale
    TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2013, 21 (03): : 699 - 705
  • [10] A clinical risk score to identify patients at high risk of very late stent thrombosis
    Godschalk, Thea C.
    Gimbel, Marieke E.
    Nolet, Wouter W.
    van Kessel, Dionne J.
    Amoroso, Giovanni
    Dewilde, Willem J.
    Wykrzykowska, Joanna J.
    Janssen, Paul W.
    Bergmeijer, Thomas O.
    Kelder, Johannes C.
    Heestermans, Ton
    ten Berg, Jurrien M.
    JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2018, 31 (02) : 159 - 169